BACKGROUND: Recipients of ABO-incompatible (ABOi) living-donor kidney transplants often undergo more intense immunosuppression than their ABO-compatible counterparts. It is unknown if this difference leads to higher cancer risk after transplantation. Single-center studies are too small and lack adequate duration of follow-up to answer this question. METHODS: We identified 318 ABOi recipients in the Transplant Cancer Match Study, a national linkage between the Scientific Registry of Transplant Recipients and population-based U.S. cancer registries. Seven cancers (non-Hodgkin lymphoma, Merkel cell carcinoma, gastric adenocarcinoma, hepatocellular carcinoma, thyroid cancer, pancreatic cancer, and testicular cancer) were identified among ABOi recipients. We then matched ABOi recipients to ABO-compatible controls by age, gender, race, human leukocyte antigen mismatch, retransplantation, and transplant year. RESULTS: There was no demonstrable association between ABOi and cancer in unadjusted (incidence rate ratio, 0.83; 95% confidence interval, 0.33-1.71; P=0.3) or matched control (incidence rate ratio, 0.99; 95% confidence interval, 0.38-2.23; P=0.5) analyses. CONCLUSION: To the extent that could be determined in this registry study, current desensitization protocols are not associated with increased risk of cancer after transplantation.
BACKGROUND: Recipients of ABO-incompatible (ABOi) living-donor kidney transplants often undergo more intense immunosuppression than their ABO-compatible counterparts. It is unknown if this difference leads to higher cancer risk after transplantation. Single-center studies are too small and lack adequate duration of follow-up to answer this question. METHODS: We identified 318 ABOi recipients in the Transplant Cancer Match Study, a national linkage between the Scientific Registry of Transplant Recipients and population-based U.S. cancer registries. Seven cancers (non-Hodgkin lymphoma, Merkel cell carcinoma, gastric adenocarcinoma, hepatocellular carcinoma, thyroid cancer, pancreatic cancer, and testicular cancer) were identified among ABOi recipients. We then matched ABOi recipients to ABO-compatible controls by age, gender, race, human leukocyte antigen mismatch, retransplantation, and transplant year. RESULTS: There was no demonstrable association between ABOi and cancer in unadjusted (incidence rate ratio, 0.83; 95% confidence interval, 0.33-1.71; P=0.3) or matched control (incidence rate ratio, 0.99; 95% confidence interval, 0.38-2.23; P=0.5) analyses. CONCLUSION: To the extent that could be determined in this registry study, current desensitization protocols are not associated with increased risk of cancer after transplantation.
Authors: Joseph F Buell; J Trofe; M J Hanaway; T M Beebe; T G Gross; R R Alloway; M R First; E S Woodle Journal: Transplant Proc Date: 2002-08 Impact factor: 1.066
Authors: L Mellemkjaer; L Hammarstrom; V Andersen; J Yuen; C Heilmann; T Barington; J Bjorkander; J H Olsen Journal: Clin Exp Immunol Date: 2002-12 Impact factor: 4.330
Authors: Jacqueline M Garonzik Wang; Robert A Montgomery; Lauren M Kucirka; Jonathan C Berger; Daniel S Warren; Dorry L Segev Journal: Clin J Am Soc Nephrol Date: 2011-07-22 Impact factor: 8.237
Authors: Marina T van Leeuwen; Andrew E Grulich; Angela C Webster; Margaret R E McCredie; John H Stewart; Stephen P McDonald; Janaki Amin; John M Kaldor; Jeremy R Chapman; Claire M Vajdic Journal: Blood Date: 2009-05-14 Impact factor: 22.113
Authors: Robert A Montgomery; Jayme E Locke; Karen E King; Dorry L Segev; Daniel S Warren; Edward S Kraus; Matthew Cooper; Christopher E Simpkins; Andrew L Singer; Zoe A Stewart; J Keith Melancon; Lloyd Ratner; Andrea A Zachary; Mark Haas Journal: Transplantation Date: 2009-04-27 Impact factor: 4.939